NBIX: Neurocrine Biosciences Inc Price-to-Revenue Coefficient

Brandmark of Neurocrine (NBIX)

Neurocrine Biosciences (NBIX) minimizes capital expenditures by outsourcing manufacturing and clinical trials to external partners. The current P/S multiple illustrates the balance between market expectations and actual sales, where 4.50 determines the current status of the parameter. High patent scalability ensures massive profits with low costs, while the implementation of robotic laboratories significantly accelerates the screening of new neuropreparations.

NBIX (Neurocrine Biosciences Inc) P/S Multiple history from 07/04/2022 to 11/17/2026

Analytical breakdowns for Neurocrine Biosciences (NBIX)

General company analysis:NBIX, Neurocrine
Finished products of Neurocrine Corp

Neurocrine Biosciences (NBIX) focuses on licensing agreements and an organic development pipeline, making revenue a key value driver since profits in biotech are often secondary. This multiple compares market capitalization to sales volume, demonstrating the premium investors are willing to pay for each unit of revenue, which clearly reflects the business valuation via the P/S ratio.

Competitors of Neurocrine Biosciences

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Regencell RGC|Market Cap to Sales Volume AXSM (Axsome Therapeutics Inc)|ACADIA Pharmaceuticals - P/S Multiple|XENE - P/S Multiple|VKTX: P/S Multiple|Price-to-Sales Ratio SUPN (Supernus)|CPRX (Catalyst Pharmaceuticals Inc) - P/S Multiple|DNLI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio harmonybiosciences.com (HRMY)|Biohaven - Market Cap to Revenue Ratio|P/S Multiple AMLX (amylyx.com)|Trevi Pharma (TRVI) - Price to Sales|Praxis Corp - P/S Multiple|Anavex Corp (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Prothena Biosciences - Market Capitalization-to-Revenue Ratio|ALEC (alector.com) - P/S Multiple|Market Cap to Revenue Ratio ANNX (Annexon Biosciences)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune S.A. ACIU|Price-to-Revenue Coefficient Voyager Therapeutics (VYGR)|Neumora - P/S Multiple|Price-to-Sales Ratio SCLX|Tevogen Bio Inc. (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|CGTX (cogrx.com) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue